GO:1900749 (R)-carnitine transport: Fatty Acid Oxidation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1900749 describes the directed movement of (R)-carnitine across membranes, a process essential for mitochondrial fatty acid oxidation.
• The sodium-dependent organic cation transporter OCTN2 (SLC22A5) is the principal plasma membrane transporter mediating carnitine uptake [1,4].
• Loss-of-function mutations in SLC22A5 cause primary carnitine deficiency, a disorder characterized by impaired fatty acid oxidation, cardiomyopathy, and hypoglycemia [2,7].
• The mitochondrial carnitine/acylcarnitine carrier (CAC, SLC25A20) facilitates the transport of acylcarnitines across the inner mitochondrial membrane, linking carnitine transport to energy metabolism [1,8].
• Structural studies have revealed the sodium-dependent mechanism of OCTN2, providing a framework for understanding disease-causing variants.
• Research on (R)-carnitine transport employs knockout, point-mutation, and overexpression cell models to dissect transporter function and variant effects [4,5].
Description
GO:1900749, (R)-carnitine transport, is a biological process defined as the directed movement of (R)-carnitine into, out of, or within a cell, or between cells, by means of a transporter or pore. (R)-carnitine, also known as L-carnitine, is a zwitterionic molecule that plays a critical role in cellular energy metabolism by shuttling long-chain fatty acids into mitochondria for beta-oxidation. This transport process is therefore fundamental to maintaining metabolic homeostasis, particularly in tissues with high energy demands such as the heart and skeletal muscle. The importance of (R)-carnitine transport is underscored by inherited disorders that arise from defective transport. Primary carnitine deficiency, caused by mutations in the SLC22A5 gene encoding the sodium-dependent organic cation transporter OCTN2, leads to reduced intracellular carnitine levels, impaired fatty acid oxidation, and clinical manifestations including cardiomyopathy, skeletal myopathy, and hypoglycemia [2,7]. Additionally, the mitochondrial carnitine/acylcarnitine carrier (CAC) is essential for the final step of carnitine shuttling, and its dysfunction is associated with mitochondrial myopathies [6,8]. Researchers study (R)-carnitine transport to understand its molecular mechanisms, its role in metabolic diseases, and its potential as a therapeutic target. Recent advances in structural biology and functional genomics have provided detailed insights into the transport mechanism and the impact of genetic variants [4,5]. This article synthesizes current knowledge on the genes, functions, and research methods relevant to GO:1900749, with a focus on CRISPR-based models for functional studies.
(R)-carnitine transport At A Glance
| GO ID | GO:1900749 |
|---|---|
| GO term | (R)-carnitine transport |
| Ontology | biological_process |
| Synonym | Carnitine transport; L-Carnitine transport; Vitamin BT transport; (-)-Carnitine transport |
| Major function | Mediates the movement of (R)-carnitine across membranes, enabling fatty acid oxidation and energy metabolism. |
| Key transporters | OCTN2 (SLC22A5) at the plasma membrane; CAC (SLC25A20) at the inner mitochondrial membrane [1,8]. |
| Associated diseases | Primary carnitine deficiency, mitochondrial myopathies, cardiomyopathy [2,6,7]. |
| Research methods | CRISPR knockout/knock-in, transport assays, structural biology, functional genomics [4,5]. |
What Is GO:1900749?
GO:1900749, (R)-carnitine transport, refers to the directed movement of the (R)-carnitine molecule (also known as L-carnitine) across cellular membranes. This process is mediated by specific transporter proteins that facilitate the uptake, efflux, or intracellular distribution of carnitine. It is a biological process that is essential for the transport of fatty acids into mitochondria for energy production.
Why Is (R)-carnitine transport Important in Cell Biology?
(R)-carnitine transport is critical for cellular energy metabolism because it supplies carnitine to the mitochondrial matrix, where it is required for the carnitine shuttle that transports long-chain fatty acids for beta-oxidation. Defects in this process lead to severe metabolic disorders, including primary carnitine deficiency and mitochondrial myopathies, highlighting its clinical relevance [2,7]. Understanding the molecular mechanisms of carnitine transport is therefore essential for developing diagnostic and therapeutic strategies for these diseases.
• Enables mitochondrial fatty acid oxidation by providing carnitine for the carnitine shuttle.
• Defects in carnitine transport cause primary carnitine deficiency, characterized by cardiomyopathy and hypoglycemia [2,7].
• The mitochondrial carnitine/acylcarnitine carrier (CAC) is essential for energy production and its dysfunction leads to mitochondrial myopathies [6,8].
• Carnitine transport is important for cardiac function, as the heart relies heavily on fatty acid oxidation.
• Genetic variants in SLC22A5 affect transporter function and can be analyzed using functional genomics.
• Structural insights into OCTN2 provide a basis for understanding substrate specificity and disease mechanisms.
• Carnitine transport is a target for pharmacological modulation, with implications for metabolic disorders.
• Research on carnitine transport informs the development of newborn screening and diagnostic tools.
• Carnitine transport intersects with amino acid metabolism and mitochondrial bioenergetics.
• Studying carnitine transport helps elucidate the pathophysiology of secondary carnitine deficiencies.
What Happens During (R)-carnitine transport?
Uptake of (R)-carnitine across the plasma membrane
In simple terms: Carnitine is brought into the cell from the bloodstream by a specific transporter.
The primary transporter responsible for carnitine uptake into cells is OCTN2 (SLC22A5), a sodium-dependent organic cation transporter located in the plasma membrane. OCTN2 couples the inward transport of carnitine to the sodium gradient, allowing cells to accumulate carnitine against its concentration gradient. This step is rate-limiting for cellular carnitine availability and is essential for subsequent fatty acid oxidation.
Intracellular trafficking and mitochondrial import
In simple terms: Once inside the cell, carnitine is moved into mitochondria where it is needed for energy production.
After uptake, carnitine is distributed within the cell and enters the mitochondrial matrix via the mitochondrial carnitine/acylcarnitine carrier (CAC, also known as SLC25A20) [1,8]. CAC catalyzes the exchange of carnitine and acylcarnitines across the inner mitochondrial membrane, a critical step in the carnitine shuttle that transfers fatty acids for beta-oxidation. This transport is tightly linked to the mitochondrial membrane potential and the availability of substrates.
Role in the carnitine shuttle and fatty acid oxidation
In simple terms: Carnitine acts as a shuttle to carry fatty acids into the mitochondria to be burned for energy.
Within the mitochondrial matrix, carnitine is used by carnitine palmitoyltransferase enzymes to convert long-chain acyl-CoA into acylcarnitines, which are then transported back across the inner membrane by CAC. This carnitine shuttle is essential for the beta-oxidation of long-chain fatty acids, a major source of ATP in tissues such as heart and skeletal muscle. Defects in any component of this shuttle, including carnitine transport, lead to impaired energy production and metabolic disease.
Efflux and regulation of carnitine levels
In simple terms: Cells can also export carnitine to maintain balance.
Carnitine efflux from cells is less well characterized but may involve members of the OCTN family or other transporters. Cellular carnitine levels are regulated by a balance between uptake, efflux, and intracellular synthesis, although humans obtain most carnitine from the diet. The expression and activity of OCTN2 can be modulated by transcriptional and post-translational mechanisms, influencing overall carnitine homeostasis.
Structural basis of sodium-dependent carnitine transport
In simple terms: The transporter changes shape to move carnitine across the membrane using sodium.
Recent structural studies of OCTN2 have revealed the molecular basis of sodium-dependent carnitine transport, showing how the protein binds sodium and carnitine and undergoes conformational changes to translocate the substrate. These insights help explain how disease-associated mutations impair transport activity and provide a framework for predicting variant effects [4,5].
Key Genes Involved in GO:1900749 (R)-carnitine transport
The following genes encode proteins directly involved in (R)-carnitine transport or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC22A5 | Encodes OCTN2, the primary sodium-dependent carnitine transporter at the plasma membrane. | Mutations cause primary carnitine deficiency; target for functional studies and variant analysis [2,4]. |
| SLC25A20 | Encodes the mitochondrial carnitine/acylcarnitine carrier (CAC) that transports carnitine and acylcarnitines across the inner mitochondrial membrane [1,8]. | Defects cause carnitine-acylcarnitine translocase deficiency; studied for mitochondrial fatty acid oxidation. |
| CPT1A | Carnitine palmitoyltransferase 1A, catalyzes the first step of the carnitine shuttle. | Key enzyme in fatty acid oxidation; mutations cause CPT1A deficiency. |
| CPT2 | Carnitine palmitoyltransferase 2, catalyzes the reverse reaction in the mitochondrial matrix. | Defects cause CPT2 deficiency, a disorder of fatty acid oxidation. |
| SLC25A29 | Mitochondrial carnitine/acylcarnitine carrier-like protein, may transport carnitine derivatives. | Potential alternative transporter; less characterized. |
| SLC22A4 | Encodes OCTN1, a related organic cation transporter that can transport carnitine with lower affinity. | May contribute to carnitine transport in specific tissues; studied for substrate specificity. |
| SLC22A16 | Encodes OCTN3, a carnitine transporter expressed in testis and other tissues. | Potential role in male fertility and carnitine homeostasis. |
| PPARGC1A | PGC-1alpha, transcriptional coactivator that regulates mitochondrial biogenesis and fatty acid oxidation genes. | May indirectly regulate carnitine transport by controlling expression of transporters. |
| Nrf2 (NFE2L2) | Transcription factor that regulates antioxidant response and may influence carnitine transport under stress. | Potential regulator of SLC22A5 expression; studied in oxidative stress contexts. |
| TFEB | Transcription factor EB, master regulator of lysosomal and metabolic gene expression. | May regulate expression of carnitine transporters; links to autophagy and metabolism. |
| SREBF1 | Sterol regulatory element-binding transcription factor 1, regulates lipid metabolism genes. | Potential regulator of carnitine transport in response to lipid status. |
| HNF4A | Hepatocyte nuclear factor 4 alpha, regulates genes involved in lipid and glucose metabolism. | May control SLC22A5 expression in liver and kidney. |
| CREB1 | cAMP response element-binding protein, regulates metabolic gene expression. | Potential regulator of carnitine transport under hormonal control. |
| SP1 | Specificity protein 1, a ubiquitous transcription factor that binds GC-rich promoters. | May regulate basal expression of SLC22A5. |
| YY1 | Yin Yang 1, a multifunctional transcription factor. | Potential regulator of carnitine transporter genes. |
| CTNNB1 | Beta-catenin, involved in cell adhesion and Wnt signaling. | May influence carnitine transport in cancer and development. |
| EPAS1 | Hypoxia-inducible factor 2 alpha, regulates response to hypoxia. | May modulate carnitine transport under hypoxic conditions. |
| PPARA | Peroxisome proliferator-activated receptor alpha, key regulator of fatty acid oxidation. | Regulates expression of carnitine shuttle genes; target for metabolic studies. |
How Is (R)-carnitine transport Regulated?
The transport of (R)-carnitine is regulated at multiple levels. The expression of SLC22A5 (OCTN2) can be influenced by transcription factors such as PPAR alpha, which governs fatty acid oxidation genes. Additionally, the activity of OCTN2 can be modulated by post-translational modifications and membrane trafficking. The mitochondrial carnitine/acylcarnitine carrier (CAC) is regulated by the mitochondrial membrane potential and by substrates of the carnitine shuttle. Hormonal signals, such as insulin and glucagon, may also affect carnitine transport indirectly by altering metabolic demand.
(R)-carnitine transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC22A5 | Primary carnitine deficiency; cardiomyopathy, hypoglycemia [2,7] | Knockout HEK293 or HeLa cells; patient-derived fibroblasts; knock-in of patient variants |
| SLC25A20 | Carnitine-acylcarnitine translocase deficiency; mitochondrial myopathy [6,8] | Knockout HepG2 cells; mitochondrial transport assays |
| CPT2 | CPT2 deficiency; rhabdomyolysis, hypoglycemia | Knockout myotubes; fatty acid oxidation flux assays |
| CPT1A | CPT1A deficiency; hypoketotic hypoglycemia | Knockout hepatocytes; lipid metabolism studies |
| SLC22A4 | Inflammatory bowel disease; carnitine transport modulation | Overexpression in Caco-2 cells; transport assays |
Primary carnitine deficiency
Primary carnitine deficiency is an autosomal recessive disorder caused by mutations in SLC22A5, which encodes the OCTN2 carnitine transporter [2,7]. Loss of OCTN2 function leads to reduced cellular carnitine uptake, impaired fatty acid oxidation, and clinical features such as cardiomyopathy, skeletal myopathy, hypoglycemia, and Reye syndrome. Newborn screening and functional studies of SLC22A5 variants are critical for diagnosis and management.
Mitochondrial myopathies and carnitine shuttle defects
Defects in the mitochondrial carnitine/acylcarnitine carrier (CAC, encoded by SLC25A20) cause carnitine-acylcarnitine translocase deficiency, a severe disorder presenting with hypoketotic hypoglycemia, cardiomyopathy, and muscle weakness [6,8]. Mitochondrial myopathies can also result from mutations in other components of the carnitine shuttle, such as CPT2, leading to impaired energy production.
Cardiac dysfunction and carnitine transport
The heart relies heavily on fatty acid oxidation for ATP production, making it particularly sensitive to defects in carnitine transport. Studies have shown that myocardial carnitine transport is essential for normal cardiac function, and its impairment contributes to cardiomyopathy in primary carnitine deficiency and other metabolic disorders [3,7].
Pharmacological and pathophysiological modulation
The mitochondrial carnitine/acylcarnitine carrier can be inhibited by itaconate through irreversible binding to cysteine 136, suggesting a link between inflammation and carnitine transport. This finding has implications for understanding how inflammatory states may affect fatty acid oxidation and energy metabolism.
From (R)-carnitine transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SLC22A5 knockout reduce carnitine uptake? | CRISPR knockout in HEK293 or HeLa cells followed by radiolabeled carnitine uptake assay |
| How do patient variants affect OCTN2 function? | Point mutations introduced by CRISPR in SLC22A5, expressed in cells, and assayed for transport activity |
| Can wild-type SLC22A5 rescue carnitine transport in deficient cells? | Knock-in of wild-type SLC22A5 into knockout cells; functional rescue assays |
| What is the effect of SLC25A20 overexpression on fatty acid oxidation? | Overexpression of SLC25A20 in hepatoma cells; measure acylcarnitine profiles |
| Does tagged OCTN2 localize correctly? | Knock-in of fluorescent or epitope-tagged SLC22A5; imaging and subcellular fractionation |
| Can CRISPR library screening identify regulators of carnitine transport? | Genome-wide CRISPR knockout library in cells expressing a carnitine-responsive reporter |
How to Study the (R)-carnitine transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled carnitine uptake | Transport activity of carnitine transporters | Assessing OCTN2 function in knockout/overexpression cells |
| CRISPR knockout screening | Identification of genes required for carnitine transport | Genome-wide screens with carnitine-dependent reporters |
| Deep mutational scanning | Effect of variants on transporter function | Variant classification in primary carnitine deficiency |
| Cryo-EM | Three-dimensional structure of transporter | Understanding sodium-dependent transport mechanism |
| Acylcarnitine profiling | Levels of acylcarnitines as markers of fatty acid oxidation | Diagnosis of carnitine shuttle disorders |
| Immunofluorescence | Subcellular localization of transporters | Validating tagged knock-in cell lines |
| RNA-seq | Expression of carnitine transport genes | Regulatory studies and disease models |
| Proteomics | Protein abundance and modifications | Post-translational regulation of OCTN2 |
Transport assays
Radiolabeled carnitine uptake assays are used to measure the activity of carnitine transporters in cells and membrane vesicles. These assays can be performed in knockout or overexpression cell lines to determine the contribution of specific transporters.
Functional genomics and variant analysis
Deep mutational scanning and functional genomics approaches, such as those used to study OCTN2 variants, allow systematic assessment of the impact of genetic variants on carnitine transport. These methods combine CRISPR-based editing with high-throughput sequencing to link genotype to phenotype.
Structural biology
Cryo-electron microscopy and X-ray crystallography have been used to determine the structure of OCTN2, revealing the sodium-dependent transport mechanism. Structural studies provide a framework for understanding how mutations affect protein function.
Metabolic profiling
Mass spectrometry-based metabolomics and acylcarnitine profiling are used to assess the consequences of altered carnitine transport on cellular metabolism. These methods can detect changes in fatty acid oxidation intermediates in cells and tissues.
How CRISPR Can Be Used to Study GO:1900749 (R)-carnitine transport
Knockout
CRISPR knockout of SLC22A5 or SLC25A20 in cell lines such as HEK293 or HeLa provides a clean background to study carnitine transport deficiency. These models can be used to measure baseline carnitine uptake and to test the function of introduced variants.
Point Mutation
Introducing specific patient-associated point mutations into SLC22A5 via CRISPR base editing or homology-directed repair allows functional assessment of variants. Such models help determine which mutations are pathogenic and inform variant classification.
Knock-in
Knock-in of wild-type or tagged SLC22A5 into a knockout background can rescue carnitine transport and enable localization studies. Tagged knock-in models are valuable for imaging transporter trafficking and interactions.
Overexpression
Overexpression of SLC22A5 or SLC25A20 in cell lines can enhance carnitine transport and fatty acid oxidation, providing a system to study regulation and substrate specificity. Overexpression models are also useful for structural and biochemical studies.
How EDITGENE Supports (R)-carnitine transport Research
Researchers studying (R)-carnitine transport-related genes often need to determine whether a candidate gene is causally involved in carnitine uptake, metabolism, or disease. CRISPR-based cell models provide a robust platform to dissect gene function and variant effects.
Contact EDITGENE today to design your custom CRISPR model for (R)-carnitine transport research.
Frequently Asked Questions About (R)-carnitine transport
What is (R)-carnitine transport?
(R)-carnitine transport is the biological process of moving the molecule (R)-carnitine across cell membranes, mediated by specific transporter proteins, and is essential for fatty acid oxidation.
What genes are involved in (R)-carnitine transport?
Key genes include SLC22A5 (OCTN2) for plasma membrane uptake, SLC25A20 (CAC) for mitochondrial transport, and CPT1A/CPT2 for the carnitine shuttle [1,8].
What is the function of GO:1900749?
GO:1900749 describes the directed movement of (R)-carnitine into, out of, or within cells, enabling mitochondrial fatty acid oxidation and energy production.
Which diseases are linked to (R)-carnitine transport defects?
Defects cause primary carnitine deficiency, cardiomyopathy, skeletal myopathy, and mitochondrial myopathies [2,6,7].
How is (R)-carnitine transport studied?
Researchers use radiolabeled uptake assays, CRISPR knockout/knock-in cell models, structural biology, and metabolomics [4,5].
What is the role of OCTN2 in carnitine transport?
OCTN2 (SLC22A5) is the primary sodium-dependent carnitine transporter that mediates uptake of carnitine into cells [1,4].
Can CRISPR be used to study carnitine transport?
Yes, CRISPR knockout, point mutation, and knock-in models are powerful tools to dissect the function of carnitine transporters and variants.
What is primary carnitine deficiency?
It is an inherited disorder caused by mutations in SLC22A5, leading to reduced carnitine transport, impaired fatty acid oxidation, and symptoms like cardiomyopathy and hypoglycemia [2,7].
How does the mitochondrial carnitine carrier work?
The carnitine/acylcarnitine carrier (CAC, SLC25A20) exchanges carnitine and acylcarnitines across the inner mitochondrial membrane, a key step in the carnitine shuttle.
What model systems are available for carnitine transport research?
Common models include HEK293, HeLa, and HepG2 cells with CRISPR modifications, as well as patient-derived fibroblasts [4,5].
Conclusion
(R)-carnitine transport (GO:1900749) is a fundamental biological process that ensures the availability of carnitine for mitochondrial fatty acid oxidation. Its disruption leads to severe metabolic disorders, underscoring its clinical importance. Advances in structural biology and functional genomics have illuminated the molecular mechanisms of key transporters such as OCTN2 and CAC [4,5]. CRISPR-based cell models offer powerful tools to study these transporters, evaluate genetic variants, and develop potential therapies for carnitine transport deficiencies.
References
- 1. Longo N et al.. 2016. Carnitine transport and fatty acid oxidation.. Biochim Biophys Acta 1863(10):2422-35 PMID: 26828774
- 2. Frigeni M et al.. 2017. Functional and molecular studies in primary carnitine deficiency.. Hum Mutat 38(12):1684-1699 PMID: 28841266
- 3. Siliprandi N et al.. 1987. Myocardial carnitine transport.. Basic Res Cardiol 82 Suppl 1:53-62 PMID: 3311009
- 4. Koleske ML et al.. 2022. Functional genomics of OCTN2 variants informs protein-specific variant effect predictor for Carnitine Transporter Deficiency.. Proc Natl Acad Sci U S A 119(46):e2210247119 PMID: 36343260
- 5. Davies JS et al.. 2025. Structural basis of sodium ion-dependent carnitine transport by OCTN2.. Nat Commun 17(1):181 PMID: 41318751
- 6. DiMauro S et al.. 1987. Mitochondrial myopathies.. J Inherit Metab Dis 10 Suppl 1:113-28 PMID: 2824920
- 7. Longo N et al.. 2006. Disorders of carnitine transport and the carnitine cycle.. Am J Med Genet C Semin Med Genet 142C(2):77-85 PMID: 16602102
- 8. Giangregorio N et al.. 2023. Inhibition of the Mitochondrial Carnitine/Acylcarnitine Carrier by Itaconate through Irreversible Binding to Cysteine 136: Possible Pathophysiological Implications.. Biomolecules 13(6) PMID: 37371573
